Popular terms

Bowel topics
Bowel Disease
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Inflammation
Mercaptopurine
Probiotics
Abdominal Pain
Discomfort
Bowel Movement
Gastrointestinal
Ulcerative Colitis
Rheumatoid Arthritis
Jejunal Tube
Spring Mechanism
Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Bowel patents



      

This page is updated frequently with new Bowel-related patent applications.




Date/App# patent app List of recent Bowel-related patents
02/04/16
20160032363 
 Methods for the diagnosis and treatment of inflammatory bowel disease patent thumbnailMethods for the diagnosis and treatment of inflammatory bowel disease
There is provided methods and compositions to diagnose, classify and treat inflammatory bowel disease including ulcerative colitis and crohn's disease by measuring the levels of certain bacterial taxa and proteins collected from the gut.. .
University Of Ottawa


01/28/16
20160024082 
 P2x7 modulators patent thumbnailP2x7 modulators
The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/28/16
20160024031 
 Heterocyclic compounds useful in the treatment of disease patent thumbnailHeterocyclic compounds useful in the treatment of disease
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (rs)-3-cyclopropyl-2-{4-[3-methyl-4((r)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (r)-1-(4′-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid..
Epigen Biosciences, Inc.


01/28/16
20160022873 
 Tissue engineered intestine patent thumbnailTissue engineered intestine
The invention provides for engineered intestinal construct and methods of making these constructs. The invention also provides for methods of treating short bowel syndrome or methods of repairing an intestine after resection comprising inserting an engineered intestinal construct into the intestine of a subject in need..
Nanofiber Solutions Llc


01/28/16
20160022794 
 Siderophore-based immunization against gram-negative bacteria patent thumbnailSiderophore-based immunization against gram-negative bacteria
The present invention provides novel enterobactin-carrier protein conjugates and salmochelin-carrier protein conjugates, such as compounds of formula (i), and salts thereof. The present invention also provides compositions, kits, and methods that involve the compounds of formula (i) and are useful in inducing an immune response, treating a bacterial infection and/or inflammatory bowel disease in a subject, preventing a bacterial infection and/or inflammatory bowel disease in a subject, or inhibiting the growth of or killing a bacterium..
The Regents Of The University Of California


01/28/16
20160022767 
 Protein particles comprising disulfide crosslinkers and uses patent thumbnailProtein particles comprising disulfide crosslinkers and uses
This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.
Emory University


01/28/16
20160022759 
 Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis patent thumbnailMethods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis
Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences


01/28/16
20160022702 
 Methods for treating inflammation, autoimmune disorders and pain patent thumbnailMethods for treating inflammation, autoimmune disorders and pain
Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (csa), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein..

01/28/16
20160022592 
 Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents patent thumbnailTargeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.. .
Therabiome, Llc


01/28/16
20160022511 
 Devices and methods for treating accidental bowel leakage patent thumbnailDevices and methods for treating accidental bowel leakage
Described here are body liners and methods for treating accidental bowel leakage using one or more body liners. The body liners may be formed from one or more liner layers and in some instances may comprise one or more adhesive regions to connect the body liners to the skin of a wearer.
Butterfly Health, Inc.


01/21/16
20160016962 

P2x7 modulators


The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/21/16
20160015779 

Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists, and immunotoxins


This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. Tnfr25 agonists disclosed herein have an anti-inflammatory and healing effect.
University Of Miami


01/14/16
20160009802 

Type 3 innate lymphoid cell induced gastrointestinal tract mucosal healing


Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (gi) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (mnps) in the gi tract and, in turn, regulate the activity of interleukin (il)-22-producing group 3 innate lymphoid cells (ilc3) in close proximity thereto..

01/14/16
20160008395 

Process for the preparation of a non-corrosive base solution and methods of using same


The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production including, but not limited to, gout, lesch-nyhan syndrome, hemochromatosis, alzheimer's, amyotropic lateral sclerosis, arthritis, atherosclerosis, cancer, cataracts, chronic obstructive pulmonary disease, diabetes, cellulitis, coronary artery disease, heart failure, hypertension, inflammatory bowel disease, macular degeneration, multiple sclerosis, parkinson's, reynaud's phenomenon, reperfusion injury, pancreatic impairment, skin infections, hepatitis c, methicillin-resistant staphylococcus aureus and infection.

01/14/16
20160008331 

Compositions and methods for treating inflammatory bowel disease


The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent.
The Johns Hopkins University


01/07/16
20160002730 

Method for classifying an inflammatory bowel disease as a crohn's disease or as an ulcerative colitis


The present invention relates to a method for classifying an inflammatory bowel disease in a patient as a crohn's disease or as an ulcerative colitis, said method comprising a step of measuring an expression profile of mirna in a sample from the patient, wherein said mirna are mir15a, mir26a, mir29a, mir29b, mir30c, mir126*, mir127-3p, mir-142-3p, mir-142-5p, mir-146a, mir-146b-5p, mir150, mir-181d, mir-182, mir185, mir196a, mir199a-3p, mir199a-5p, mir199b-5p, mir-203, mir223, mir-299-5p, mir320a, mir324-3p, mir-328.. .
Institut National De La Sante Et De La Recherche Medicale (inserm)


01/07/16
20160002327 

Methods of purifying anti-interleukin-13 antibodies


The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and hodgkin's lymphoma, particularly asthma.. .
Medimmune Limited


01/07/16
20160002215 

Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors


This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. .
Glaxosmithkline Intellectual Property Development Limited


01/07/16
20160000839 

Compositions and treatment and prophylaxis of inflammatory bowel disease


Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic.

01/07/16
20160000838 

Use of faecalibacterium prausnitzii htf-f (dsm 26943) to suppress inflammation


The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease.
Academisch Ziekenhuis Groningen


01/07/16
20160000783 

Trk-inhibiting compound


The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an n-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease..
Ono Pharmaceutical Co., Ltd.


01/07/16
20160000765 

Methods for treating bowel diseases


The present invention provides new methods of treating bowel disease (bd) by increasing a durability of response; treating bd in males; treating bd in adolescent subjects; treating bloating due to bd in males; and methods of maintaining remission of bd.. .
Salix Pharmaceuticals, Inc.


01/07/16
20160000734 

Method and compositions of civamide to treat disease of the intestines


Compositions and a methods are described for treating disorders of the small and large bowel, such as crohn's disease, ulcerative colitis and irritable bowel syndrome, without producing any treatment-related systemic side effects and with minimal or no abdominal discomfort. A method of administration of civamide that is incorporated into soft gelatin capsules and administered with meals is described.
Winston Laboratories, Inc.


01/07/16
20160000728 

Multiparticulate l-menthol formulations and related methods


An l-menthol pharmaceutical dosage form includes an effective amount of l-menthol for treating a gastrointestinal disorder. The l-menthol is within a plurality of particulates having a core and an enteric coating over the core.
Zx Pharma, Llc


12/31/15
20150376707 

Methods of diagnosing and treating inflammatory bowel disease


The present invention also provides various methods, kits and compositions for diagnosing, prognosing, and treating various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and crohn's disease. Also, the present invention provides various methods, kits and compositions for determining susceptibility to or a low probability of various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and crohn's disease.
Cedars-sinai Medical Center


12/31/15
20150376696 

Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease


Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient..
Children's Hospital Medical Center D/b/a Cincinnati Children's Hospital Medical Center


12/31/15
20150376174 

Azole benzene derivative


The present invention provides: a compound represented by formula (i) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.. .
Teijin Pharma Limited


12/31/15
20150374776 

Use of fermented wheat germ in the treatment of inflammatory bowel disease


The present invention provides a fermented dried material derived from the fermented liquid obtainable by fermenting wheat germ with saccharomyces cerevisiae in an aqueous medium for use in the treatment of inflammatory bowel disease. Methods of treating and/or preventing an inflammatory bowel disease are also described..
3ch Ltd


12/31/15
20150374709 

Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use


Disclosed are nordihydroguaiarctic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue o groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as hiv infection, hpv infection, or hsv infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.. .
Erimos Pharmaceuticals Llc


12/24/15
20150368314 

Glucagon-like-peptide-2 (glp-2) analogues


Glp-2 analogues are disclosed which comprise one of more substitutions as compared to [hgly2]glp-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred glp-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type glp-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a n-terminal or c-terminal stabilizing peptide sequence.
Zealand Pharma A/s


12/24/15
20150367111 

Ostomy pump system and related methods of use and manufacture


A device for refeeding bowel content of a subject configured to cover a proximal ostomy of a subject and a distal member configured to cover a distal ostomy of a subject. The device may include a bowel lumen member configured to carry bowel contents between the proximal ostomy and the distal ostomy.
University Of Virginia Patent Foundation


12/24/15
20150366415 

Sanitary napkin


A sanitary napkin for clean or dry a user's rectal and genital area. The sanitary napkin has a first side, a second side, and a pair of opposing ends, wherein the ends are tapered and form a pointed structure.

12/17/15
20150361161 

Antigens associated with inflammatory bowel disease


Specific binding members that bind the ed-a isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (ibd), and/or for use in delivery to the ibd tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10..
Philogen S.p.a.


12/17/15
20150361139 

Crystalline form of linaclotide


Linaclotide is a guanylate cyclase type c receptor (gcc) agonist used in the treatment of gastrointestinal disorders and conditions, including irritable bowel syndrome and chronic constipation. Crystalline form ii of linaclotide is prepared in high purity and yields and shows superior chemical stability in comparison to known crystal or amorphous forms of linaclotide.
Sandoz Ag


12/17/15
20150359836 

Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment


The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors.
Nordisk Rebalance A/s


12/17/15
20150359787 

Tetrahydroisoquinolin-1-one derivative or salt thereof


To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (ibs). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (bb2) receptor antagonistic action.
Seldar Pharma Inc.




Bowel topics: Bowel Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Inflammation, Mercaptopurine, Probiotics, Abdominal Pain, Discomfort, Bowel Movement, Gastrointestinal, Ulcerative Colitis, Rheumatoid Arthritis, Jejunal Tube, Spring Mechanism, Small Bowel

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5373

5239

2 - 1 - 103